-
Inmagene’s Tavalisse First Prescribed in China for ITP Treatment
•
China-based Inmagene Biopharmaceuticals has announced that its in-licensed drug Tavalisse (fostamatinib) has been first prescribed at the Hainan branch of Shanghai’s Ruijin Hospital. This marks a significant milestone in the availability of the oral spleen tyrosine kinase (SYK) inhibitor for the treatment of immunization thrombocytopenia (ITP) in China. Background and…
-
BrightGene’s Generic Halaven Approved for Marketing in China
•
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Japan-based Eisai’s (TYO: 4523) cancer therapy Halaven (eribulin). The approval signifies that BrightGene’s product, trade-named BoLiNing, has passed the generic quality consistency evaluation (GQCE). BoLiNing is…
-
Abcam and MEDx Expand Strategic Partnership on Claudin 18.2 Diagnosis
•
UK-based abcam (NASDAQ:ABCM) has announced a licensing agreement with China-headquartered MEDx Translational Medicine Co., Ltd, further expanding their strategic partnership initiated in 2021. The collaboration will focus on development, regulatory filings, and commercialization related to Claudin 18.2 concomitant diagnosis. Financial details of the agreement were not disclosed. About AbcamAbcam is…
-
Inovio and ApolloBio Announce Positive Phase III Data for VGX-3100 Vaccine
•
US-based Inovio Pharmaceuticals (NASDAQ: INO) and China-based ApolloBio Corp. (NEEQ:430187) have announced positive data from the Phase III Reveal 2 study for the DNA therapeutic vaccine VGX-3100 (known as ABC-3100 in China). The two firms are co-developing VGX-3100 under a 2018 licensing deal, with ApolloBio holding development and commercialization rights…
-
Neo Modulus Secures Series B Funding for Regenerative Medical Device Development
•
Neo Modulus, a developer of regenerative implantable medical devices based in Suzhou, has reportedly raised “hundreds of millions” of renminbi in a Series B financing round. The round was led by SND Financial Holdings, with participation from JM Capital, CDH Investments, Hui Ding Capital, 10Fund, and Boya Clivia Venture Capital.…
-
Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions
•
Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity (mobocertinib) in China. The Japanese pharmaceutical giant will partner with China-based health platform MediTrust Health to launch innovative payment solutions for the drug in China, making this advanced therapy more accessible to patients. Clinical Need…
-
Harbour BioMed’s Batoclimab Shows Positive Results in gMG Phase III Trial
•
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands, and Suzhou (China), has announced positive topline results from its phase III clinical trial of batoclimab (HBM9161) for the treatment of generalized myasthenia gravis (gMG). The pivotal clinical study, designed to confirm the efficacy and…
-
BGI Group Subsidiaries Added to US Trade Blacklist by Commerce Department
•
The US Department of Commerce (DOC)’s Bureau of Industry and Security (BIS) has added 37 companies from various countries and industries to its trade blacklist, including 28 Chinese entities. Among the China-based companies are three subsidiaries of genomics giant BGI Group: BGI Research, BGI Tech Solutions (Hongkong) Co., Ltd, and…
-
Sanyou Biopharmaceuticals Expands Global Reach with New Cambridge Office
•
Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is set to open a new office in the Cambridge Innovation Centre (CIC) on March 2, 2023. This strategic move marks a significant step forward in expanding the company’s global footprint and enhancing its capabilities to serve and collaborate with biotechs…
-
Sanofi’s Dupixent Receives Priority Review for Prurigo Nodosa Treatment
•
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status from the Center for Drug Evaluation (CDE) for its Dupixent (dupilumab) to treat prurigo nodosa (PN) in adults. This marks another significant breakthrough in the type 2 inflammation field, following the drug’s indication approval for…
-
Eli Lilly’s Retevmo Launched in China by Innovent Biologics
•
Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese market. The drug is being commercialized by domestic firm Innovent Biologics Inc. (HKEX: 01801) under a partnership deal signed between the two companies in March last year. This collaboration aims to bring innovative treatments to…
-
QL Biopharm Raises Series B Funding for Protein Drug Development
•
QL Biopharm, a Beijing-based developer of Escherichia coli-based protein drugs, has reportedly raised RMB 100 million (USD 14.46 million) in a Series B financing round. The round was led by Bluerun Ventures, with additional participation from Taizhou Pharmaceutical Hi-tech Zone Huayin Financial Investment, Lichen Private Equity Fund, and Mingfeng Capital.…
-
Huahai Pharma’s HB0025 Receives NMPA Approval for Clinical Trials
•
China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for HB0025, an in-house developed bispecific antibody (BsAb) targeting programmed-death ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF). The BsAb will be assessed in combination…
-
Hengrui’s Adebrelimab Receives NMPA Approval for Lung Cancer Treatment
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its adebrelimab (SHR-1316), a programmed death-ligand 1 (PD-L1) monoclonal antibody (mAb). The molecule is now approved for use in combination with chemotherapy to treat first-line extensive stage small-cell lung…
-
Siyi Intelligence Raises Series A Funding for Neural Rehabilitation Solutions
•
Siyi Intelligence, a developer of soft rehabilitation robots based in Shanghai, has reportedly raised close to RMB 100 million (USD 14.46 million) in a Series A financing round. The round was led by Chengdu Tianfu International Bio-town’s fund, with additional contributions from Tao Capital. The proceeds will be directed towards…
-
Sino Biopharmaceutical’s Bevacizumab Biosimilar Approved by NMPA
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its bevacizumab biosimilar. The approved indications for the biosimilar include the treatment of metastatic colorectal cancer (CRC), recurrent glioblastoma, and advanced metastatic or recurrent non-small cell lung cancer (NSCLC).…
-
Mabwell’s 9MW3911 Monoclonal Antibody Accepted for NMPA Review
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that a clinical trial filing for its 9MW3911, a non-IL-2 blocking CD25 monoclonal antibody (mAb) developed via the high-efficiency B lymphocyte screening platform, has been accepted for review by the National Medical Products Administration (NMPA). The targeted indication for this…
-
Venus Medtech Completes Patient Enrollment for Liwen RF Ablation System Study
•
China-based Venus Medtech (Hangzhou) Inc. (HKG: 2500) has announced that all patients have been successfully enrolled in a confirmatory study in China for its Liwen RF ablation system, designed for the treatment of hypertrophic cardiomyopathy (HCM). This marks a significant step forward in the clinical development of this innovative device.…
-
PulseCare Raises Pre-Series A Funding for Minimally Invasive Treatment Devices
•
PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The round was led by Kangju Venture Capital and Tsinghua Innovation Ventures. The proceeds will be directed towards clinical studies and the development of new product…
